This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ASCO, CHICAGO, IL, USA, 31 May-4 JUNE 2019

XENERA™-1: A phase II trial of xentuzumab in combination with everolimus and exemestane in patients with hormone-receptor positive, human epidermal growth factor receptor-2-negative metastatic breast cancer and non-visceral involvement

Peter Schmid, Hope S. Rugo, Javier Cortés, Dennis Chin-Lun Huang, Kate Crossley, Dan Massey, Howard A. Burris

FOR HEALTHCARE PROFESSIONALS ONLY.

image